CPSF6: A Potential Drug Target and Biomarker (G11052)

Target Name: CPSF6

NCBI ID: G11052

CPSF6

CPSF6: A Potential Drug Target and Biomarker

Introduction

Cleavage and polyadenylation specific factor 6 (CPSF6) is a protein that plays a critical role in various cellular processes, including DNA replication, cell growth, and apoptosis. CPSF6 is a key regulator of polycystic ovary syndrome (PCOS), a common endocrine disorder that affects millions of women worldwide. PCOS is characterized by various physiological and clinical symptoms, including obesity, infertility, and increased risk of cardiovascular diseases.

CPSF6 is a member of the TATA-binding protein (TBP) family, which includes several transcription factors. Its main function is to regulate DNA replication, cell growth and apoptosis in the cell cycle. CPSF6 controls DNA replication by binding to specific sequences on the DNA template and plays a key role in the DNA replication process.

In recent years, scientists have discovered that abnormal expression of CPSF6 in PCOS is related to the severity and clinical manifestations of the disease. For example, studies have found that the expression level of CPSF6 increases with the progression of PCOS, and the expression level is positively correlated with the severity of the disease. In addition, the expression level of CPSF6 is also related to patients' quality of life and mental health status.

CPSF6 as a drug target

Because abnormal expression of CPSF6 in PCOS is associated with disease severity and clinical manifestations, CPSF6 has become a potential drug target. Scientists are exploring the use of CPSF6 as a new drug to treat PCOS.

For example, researchers are exploring the use of anti-CPSF6 antibodies to treat PCOS. Anti-CPSF6 antibodies can bind to CPSF6, thereby inhibiting its function. Researchers are evaluating the anti-CPSF6 antibody's efficacy in treating PCOS and studying its impact on patients' quality of life and mental health.

In addition, CPSF6 is also being studied as a biomarker for PCOS.

Protein Name: Cleavage And Polyadenylation Specific Factor 6

Functions: Component of the cleavage factor Im (CFIm) complex that functions as an activator of the pre-mRNA 3'-end cleavage and polyadenylation processing required for the maturation of pre-mRNA into functional mRNAs (PubMed:9659921, PubMed:8626397, PubMed:14690600, PubMed:29276085). CFIm contributes to the recruitment of multiprotein complexes on specific sequences on the pre-mRNA 3'-end, so called cleavage and polyadenylation signals (pA signals) (PubMed:9659921, PubMed:8626397, PubMed:14690600). Most pre-mRNAs contain multiple pA signals, resulting in alternative cleavage and polyadenylation (APA) producing mRNAs with variable 3'-end formation (PubMed:23187700, PubMed:29276085). The CFIm complex acts as a key regulator of cleavage and polyadenylation site choice during APA through its binding to 5'-UGUA-3' elements localized in the 3'-untranslated region (UTR) for a huge number of pre-mRNAs (PubMed:20695905, PubMed:29276085). CPSF6 enhances NUDT21/CPSF5 binding to 5'-UGUA-3' elements localized upstream of pA signals and promotes RNA looping, and hence activates directly the mRNA 3'-processing machinery (PubMed:15169763, PubMed:29276085, PubMed:21295486). Plays a role in mRNA export (PubMed:19864460)

The "CPSF6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CPSF6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets